share_log

HC Wainwright & Co. Reiterates Buy on Inhibikase Therapeutics, Maintains $27 Price Target

HC Wainwright & Co. Reiterates Buy on Inhibikase Therapeutics, Maintains $27 Price Target

HC Wainwright & Co.重申买入Inhibikase Therapeutics,维持27美元的目标股价
Moomoo 24/7 ·  03/07 11:26

HC Wainwright & Co. analyst Edward White reiterates Inhibikase Therapeutics (NASDAQ:IKT) with a Buy and maintains $27 price target.

HC Wainwright & Co. 分析师爱德华·怀特重申了Inhibikase Therapeutics(纳斯达克股票代码:IKT)的买入并维持27美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发